|
|
Other links at Articles > Diabetes and Endocrinology |
| 2. |
First-Line EGFR Inhibition May Benefit Selected Lung Cancer Patients
|
|
|
There is "strong evidence" that selected groups of patients with advanced non-small cell lung cancer (NSCLC) may benefit from first-line therapy with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, according to the authors of a report in the March issue of the Journal of Thoracic Oncology. Reuters Health Information
|
|
|